ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: INFO10-TH

University of Michigan O'Brien Kidney Translational Core Center

Session Information

  • Informational Posters - I
    November 07, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Educational Research

Authors

  • Pennathur, Subramaniam, University of Michigan, Ann Arbor, Michigan, United States
  • Kretzler, Matthias, University of Michigan, Ann Arbor, Michigan, United States
  • Ju, Wenjun, University of Michigan, Ann Arbor, Michigan, United States
  • Wiggins, Roger C., University of Michigan Health System, Ann Arbor, Michigan, United States
  • Brosius, Frank C., University of Arizona, Tucson, Arizona, United States
  • Bitzer, Markus, University of Michigan, Ann Arbor, Michigan, United States
  • Athey, Brian D., University of Michigan, Ann Arbor, Michigan, United States

Group or Team Name

  • C-PROBE Research Team
Description

Despite decades of research and intervention, chronic kidney diseases (CKDs) remain a diverse set of generally progressive and often poorly understood disorders which can lead to end stage renal disease (ESRD) or death, given the lack of truly effective therapies. CKDs can be halted in a minority of patients by rigorous control of blood pressure and treatment with renin-angiotensin-aldosterone system inhibitors and in rare cases, by specific interventions targeting the underlying molecular pathogenesis of the disease. However, the great majority of CKD patients continue to progress or succumb to cardiovascular disease, which is highly prevalent in individuals with CKD. In addition, while it is well-recognized that acute kidney injury (AKI) episodes are associated with an increased risk of development and progression of CKDs, the mechanisms determining the transition from acute to irreversible injury are not well understood. In other areas of medicine, the most effective interventions have resulted from a systematic molecular understanding of the biological mechanisms of disease in individual patients promoted by the use of effective prognostic biomarkers and surrogate endpoints. The mission of the Michigan O’Brien Kidney Translational Core Center (MKTC) is to continue to provide the research base investigators with the tools, technologies, expertise and learning opportunities for their transformative basic, translational and clinical studies in the broad area of renal pathobiology to impact the lives of individuals with kidney disease.
To accomplish this mission, the MKTC will: (a) create an environment that supports innovative kidney disease research; (b) attract new scientific expertise to kidney disease research; (c) provide core services that leverage funding and contribute unique expertise to maximize the efficiency and effectiveness of the research base; (d) foster interdisciplinary collaborations, especially in emerging areas of research, to catalyze new ideas and scientific approaches and (e) promote the translation of scientific discoveries from bench to bedside to community to improve public health.

Funding

  • Funding and/or programmatic support for the George M. O’Brien Kidney Translational Core Center has been provided by P30 DK081943 from the NIDDK and funds from the University of Michigan.